07:00 , Mar 28, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Mutant methionyl-tRNA synthetase for protein labeling Expression of a mutant methionyl-tRNA synthetase derived from Escherichia coli could be useful for producing modified variants of...
07:00 , Oct 6, 2008 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch...
07:00 , Sep 1, 2008 |  BC Week In Review  |  Clinical News

REP3123: Development halted

Replidyne said that as part of a restructuring it has decided to suspended development of REP3123, which was in preclinical testing. The company said it is still in the process of reviewing its strategic alternatives...
07:00 , Sep 1, 2008 |  BC Week In Review  |  Company News

Replidyne infectious news

Replidyne restructured and reduced headcount across all areas by 19 (80%) to 5. The company also suspended development of its sole remaining compound, REP3123, a preclinical methionyl tRNA synthetase (MetRS) inhibitor for Clostridium difficile-associated diarrhea....
07:00 , Jun 30, 2008 |  BC Week In Review  |  Company News

Replidyne, Daiichi Sankyo, Nippon Soda Co. Ltd. deal

Replidyne terminated its 2004 license agreement with Daiichi Sankyo’s Asubio Pharma Co. Ltd. subsidiary that gave Replidyne exclusive North American rights to develop and commercialize Asubio’s faropenem medoxomil to treat community-acquired infections (see BioCentury, Aug....
07:00 , Apr 28, 2008 |  BioCentury  |  Finance

Ebb & Flow

On Friday, investors savaged...
01:10 , Apr 24, 2008 |  BC Extra  |  Clinical News

Replidyne stops faropenem Phase III

Replidyne (NASDAQ:RDYN) discontinued enrollment in a placebo-controlled Phase III trial of faropenem medoxomil to treat acute exacerbations of chronic bronchitis (AECB). The company said it took the action to conserve cash. The AECB trial was...
08:00 , Dec 17, 2007 |  BC Week In Review  |  Company News

Replidyne infectious news

RDYN restructured and reduced headcount by 27 (33%) to 54. The company also said it will seek strategic alternatives, including making an acquisition, merging or being acquired. RDYN will continue its ongoing placebo-controlled Phase III...
08:00 , Dec 17, 2007 |  BioCentury  |  Finance

Ebb & Flow

Dashing the hopes of buysiders,...
03:29 , Dec 11, 2007 |  BC Extra  |  Company News

Replidyne restructures, seeks alternatives

RDYN restructured and reduced headcount to 54 from 81. The company also said it will seek strategic alternatives, including making an acquisition, merging or being acquired. RDYN will continue its ongoing placebo-controlled Phase III trial...